|
US2788341A
(en)
|
1953-03-06 |
1957-04-09 |
Ciba Pharm Prod Inc |
Process for the manufacture of aminoacyl compounds
|
|
US3624097A
(en)
|
1969-07-22 |
1971-11-30 |
Warner Lambert Co |
N-pyridine 5-aminooxazoles
|
|
US4109496A
(en)
|
1977-12-20 |
1978-08-29 |
Norris Industries |
Trapped key mechanism
|
|
FR2568880B1
(fr)
|
1984-08-07 |
1986-12-12 |
Synthelabo |
Derives d'acylaminomethyl-3 imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique
|
|
US4868103A
(en)
|
1986-02-19 |
1989-09-19 |
Enzo Biochem, Inc. |
Analyte detection by means of energy transfer
|
|
US5080891A
(en)
|
1987-08-03 |
1992-01-14 |
Ddi Pharmaceuticals, Inc. |
Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
|
US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
|
DE69210091T2
(de)
|
1991-05-31 |
1996-10-02 |
Sumitomo Pharma |
Leukotrien-B4-Antagonisten
|
|
DE69326967T2
(de)
|
1992-01-17 |
2000-06-15 |
Lakowicz, Joseph R. |
Phasenmodulationsenergieübertragungsfluoroimmunassay
|
|
EP1362913B1
(en)
|
1992-10-30 |
2006-01-25 |
The General Hospital Corporation |
Interaction trap system for isolating proteins
|
|
US5656465A
(en)
|
1994-05-04 |
1997-08-12 |
Therion Biologics Corporation |
Methods of in vivo gene delivery
|
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
|
US5677158A
(en)
|
1995-06-07 |
1997-10-14 |
Research Foundation Of State University Of New York |
In vitro packaging of adeno-associated virus DNA
|
|
US5801030A
(en)
|
1995-09-01 |
1998-09-01 |
Genvec, Inc. |
Methods and vectors for site-specific recombination
|
|
US6180612B1
(en)
|
1997-10-31 |
2001-01-30 |
The University Of Virginia Patent Foundation |
Methods and compositions for targeting DNA metabolic processes using aminoglycoside derivatives
|
|
US6683058B1
(en)
|
1998-04-15 |
2004-01-27 |
Regents Of The University Of California |
Methods for therapy of neurodegenerative disease of the brain
|
|
DE69929600T2
(de)
|
1998-05-27 |
2006-09-07 |
Avigen Inc., Alameda |
Konvektion-erhöhte verabreichung aadc-kodierende aav vektoren
|
|
JP2000095767A
(ja)
|
1998-09-28 |
2000-04-04 |
Takeda Chem Ind Ltd |
性腺刺激ホルモン放出ホルモン拮抗剤
|
|
WO2000024392A1
(en)
|
1998-10-26 |
2000-05-04 |
Sumitomo Pharmaceuticals Company, Limited |
β-AMYLOID FORMATION INHIBITORS
|
|
AU4058000A
(en)
|
1999-04-02 |
2000-10-23 |
Neurogen Corporation |
Aryl and heteroaryl fused aminoalkyl-imidazole derivatives: selective modulatorsof gabaa receptors
|
|
WO2000059888A1
(en)
|
1999-04-02 |
2000-10-12 |
Neurogen Corporation |
N-benzimidazolylmethyl- and n-indolylmethyl-benzamides and their use as crf modulators
|
|
WO2001059094A2
(en)
|
2000-02-11 |
2001-08-16 |
The Salk Institute For Biological Studies |
Method of regulating transcription in a cell by altering remodeling of cromatin
|
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
CA2406864A1
(en)
|
2000-02-24 |
2001-08-30 |
Life Technologies Corporation |
Simultaneous stimulation and concentration of cells
|
|
US20020037281A1
(en)
|
2000-05-26 |
2002-03-28 |
Davidson Beverly L. |
Methods of transducing neural cells using lentivirus vectors
|
|
AU2001280576A1
(en)
|
2000-07-18 |
2002-01-30 |
Uab Research Foundation |
Tissue-specific self-inactivating gene therapy vector
|
|
US20030027335A1
(en)
|
2000-09-07 |
2003-02-06 |
Ruley H. Earl |
Genome engineering by cell-permeable DNA site-specific recombinases
|
|
WO2002064834A1
(en)
|
2001-01-04 |
2002-08-22 |
Myriad Genetics, Inc. |
Novel two-hybrid system and use thereof
|
|
JP2003033179A
(ja)
|
2001-07-05 |
2003-02-04 |
Asahi Kasei Corp |
可逆的遺伝子導入ベクター
|
|
JP2003077651A
(ja)
|
2001-08-30 |
2003-03-14 |
Sharp Corp |
有機エレクトロルミネッセンス素子の製造方法
|
|
ES2367422T3
(es)
|
2001-10-09 |
2011-11-03 |
Amgen Inc. |
Derivados de imidazol como agentes antiinflamatorios.
|
|
US20050079512A1
(en)
|
2003-02-26 |
2005-04-14 |
Emerson Beverly M. |
Methods of modulating gene expression
|
|
WO2004078939A2
(en)
|
2003-03-03 |
2004-09-16 |
University Of Massachusetts |
REGULATION OF Mdm2 FUNCTION
|
|
US20050130919A1
(en)
|
2003-07-18 |
2005-06-16 |
University Of Massachusetts |
Regulatable promoters for synthesis of small hairpin RNA
|
|
WO2005039643A2
(en)
|
2003-10-20 |
2005-05-06 |
Nsgene A/S |
In vivo gene therapy of parkinson's disease
|
|
US20060058255A1
(en)
|
2004-03-01 |
2006-03-16 |
Jianzhu Chen |
RNAi-based therapeutics for allergic rhinitis and asthma
|
|
US20050289659A1
(en)
|
2004-05-18 |
2005-12-29 |
Jacks E T |
Cre-lox based method for conditional RNA interference
|
|
WO2006005941A1
(en)
|
2004-07-12 |
2006-01-19 |
Istituto Di Ricerche Di Biologia Molecolare P Angeletti S.P.A. |
Amide derivatives as inhibitors of histone deacetylase
|
|
DK1814880T3
(da)
|
2004-11-11 |
2009-05-18 |
Ferrer Int |
Imidazo[1,2-a]pyridinforbindelser, og sammensætninger, anvendelser og fremgangsmåder, der er forbundet dermed
|
|
WO2006070806A1
(ja)
|
2004-12-28 |
2006-07-06 |
Taiho Pharmaceutical Co., Ltd. |
新規ベンゾイミダゾール化合物及び該化合物を含有する医薬組成物
|
|
WO2006119435A2
(en)
|
2005-05-04 |
2006-11-09 |
Invitrogen Corporation |
Identification of cancer biomarkers and phosphorylated proteins
|
|
CN101528226B
(zh)
|
2006-08-24 |
2012-01-11 |
澳大利亚核科学技术组织 |
靶向外周苯二氮卓受体的氟化配体
|
|
US8324367B2
(en)
|
2006-11-03 |
2012-12-04 |
Medtronic, Inc. |
Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
|
|
JP2010528051A
(ja)
*
|
2007-05-23 |
2010-08-19 |
シガ・テクノロジーズ・インコーポレーテッド |
デング感染症の治療または予防のための抗ウイルス薬
|
|
US20090209536A1
(en)
|
2007-06-17 |
2009-08-20 |
Kalypsys, Inc. |
Aminoquinazoline cannabinoid receptor modulators for treatment of disease
|
|
CA2709784A1
(en)
|
2007-12-21 |
2009-07-09 |
University Of Rochester |
Method for altering the lifespan of eukaryotic organisms
|
|
CA2618163A1
(en)
|
2008-02-07 |
2009-08-07 |
K. W. Michael Siu |
Head and neck cancer biomarkers
|
|
ES2392482T3
(es)
|
2008-02-29 |
2012-12-11 |
Array Biopharma, Inc. |
Derivados de imidazo[4,5-b] piridina usados como inhibidores de RAF
|
|
EP2559455A1
(en)
|
2008-07-15 |
2013-02-20 |
Novartis AG |
Heteroaryl derivatives as DGAT1 inhibitors
|
|
MX2011008204A
(es)
|
2009-02-05 |
2011-12-06 |
Targeted Delivery Technologies Ltd |
Metodos para reducir la proliferacion y viabilidad de los agentes microbianos.
|
|
KR101609856B1
(ko)
|
2010-03-17 |
2016-04-07 |
타이벡스 세라피틱스 코포레이션 |
Ｈｅｃ１ 활성의 조절인자 및 이의 방법
|
|
US20130197056A1
(en)
|
2010-04-22 |
2013-08-01 |
British Columbia Cancer Agency Branch |
Novel biomarkers and targets for ovarian carcinoma
|
|
WO2012015937A2
(en)
|
2010-07-29 |
2012-02-02 |
The Regents Of The University Of Michigan |
Parp1 targeted therapy
|
|
US9072052B2
(en)
|
2010-08-09 |
2015-06-30 |
Blackberry Limited |
Communication system providing context-based mobile wireless communications device power consumption management and related methods
|
|
CN103429571A
(zh)
|
2010-12-22 |
2013-12-04 |
普渡制药公司 |
作为钠通道阻断剂的取代吡啶
|
|
EP2694678A2
(en)
|
2011-04-04 |
2014-02-12 |
Netherland Cancer Institute |
Methods and compositions for predicting resistance to anticancer treatment
|
|
CN114262690A
(zh)
|
2011-04-15 |
2022-04-01 |
吉恩勒克斯公司 |
减毒的痘苗病毒的克隆毒株及其使用方法
|
|
US8945861B2
(en)
|
2011-08-03 |
2015-02-03 |
Pierce Biotechnology, Inc. |
Methods for isotopically labeling biomolecules using mammalian cell-free extracts
|
|
US9403843B2
(en)
|
2012-02-01 |
2016-08-02 |
The Trustees Of Columbia University In The City Of New York |
Cysteine protease inhibitors and uses thereof
|
|
US9284283B2
(en)
|
2012-02-02 |
2016-03-15 |
Ensemble Therapeutics Corporation |
Macrocyclic compounds for modulating IL-17
|
|
EP3241902B1
(en)
|
2012-05-25 |
2018-02-28 |
The Regents of The University of California |
Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
|
|
AU2013359262C1
(en)
|
2012-12-12 |
2021-05-13 |
Massachusetts Institute Of Technology |
CRISPR-Cas component systems, methods and compositions for sequence manipulation
|
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
|
CA2894684A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Engineering and optimization of improved crispr-cas systems, methods and enzyme compositions for sequence manipulation in eukaryotes
|
|
US9410943B2
(en)
|
2013-03-14 |
2016-08-09 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods, compositions and screens for therapeutics for the treatment of synovial sarcoma
|
|
EP2971094B1
(en)
|
2013-03-15 |
2021-09-15 |
Novartis AG |
Biomarkers associated with brm inhibition
|
|
WO2014150395A1
(en)
|
2013-03-15 |
2014-09-25 |
Shifa Biomedical Corporation |
Anti-pcsk9 compounds and methods for the treatment and/or prevention of cardiovascular diseases
|
|
US10976320B2
(en)
|
2013-05-21 |
2021-04-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for identifying and treating cancer patients
|
|
ES2950424T3
(es)
|
2013-07-03 |
2023-10-09 |
Takeda Pharmaceuticals Co |
Compuesto de amida
|
|
US20160130663A1
(en)
|
2013-07-12 |
2016-05-12 |
National Cancer Center |
Method for predicting response to cancer treatment
|
|
EP3022197B1
(en)
|
2013-07-15 |
2017-09-06 |
Boehringer Ingelheim International GmbH |
Novel tetra- and pentasubstituted benzimidazolium compounds
|
|
WO2015046193A1
(ja)
|
2013-09-25 |
2015-04-02 |
塩野義製薬株式会社 |
Ｔｒｐｖ４阻害活性を有する芳香族複素環式アミン誘導体
|
|
BR112016015449A8
(pt)
|
2013-12-30 |
2020-06-09 |
Lifesci Pharmaceuticals Inc |
compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos
|
|
EP3102193B1
(en)
*
|
2014-02-06 |
2023-01-11 |
Rutgers, The State University of New Jersey |
Antibacterial agents: n(alpha)-aroyl-n-aryl-phenylalaninamides
|
|
GB201402771D0
(en)
|
2014-02-17 |
2014-04-02 |
Isis Innovation |
Biomarker & therapeutic target for sarcoma
|
|
US9546206B2
(en)
|
2014-08-08 |
2017-01-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
High affinity PD-1 agents and methods of use
|
|
WO2016054491A1
(en)
|
2014-10-03 |
2016-04-07 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
US9636323B2
(en)
|
2014-10-27 |
2017-05-02 |
Baylor College Of Medicine |
Method of treating cancer that overexpresses TopBP1
|
|
CN104530013B
(zh)
|
2014-12-04 |
2016-06-29 |
中国农业大学 |
基于吲哚环的吡唑酰胺类化合物作为农用杀菌剂的用途
|
|
US9546296B2
(en)
|
2014-12-15 |
2017-01-17 |
Ppg Industries Ohio, Inc. |
Coating compositions, coatings and methods for sound and vibration damping and water resistance
|
|
US9932340B2
(en)
|
2014-12-18 |
2018-04-03 |
Abbvie Inc. |
Substituted indoles
|
|
JP6815318B2
(ja)
|
2014-12-23 |
2021-01-20 |
ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド |
二官能性分子によって標的化タンパク質分解を誘導する方法
|
|
US9694084B2
(en)
|
2014-12-23 |
2017-07-04 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
MA41598A
(fr)
|
2015-02-25 |
2018-01-02 |
Constellation Pharmaceuticals Inc |
Composés thérapeutiques de pyridazine et leurs utilisations
|
|
US10363256B2
(en)
|
2015-03-27 |
2019-07-30 |
University Of Washington |
Methods for treatment of retinal disease by photoreceptor gene expression modulation
|
|
WO2016164482A1
(en)
|
2015-04-06 |
2016-10-13 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for treatment of heart failure
|
|
EP3108883A1
(en)
|
2015-06-22 |
2016-12-28 |
Fundació Institut de Recerca Biomèdica de Bellvitge |
Therapeutic uses of non-peptide inhibitors of the calcineurin - nfat signalling pathway
|
|
WO2017007612A1
(en)
|
2015-07-07 |
2017-01-12 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
WO2017024318A1
(en)
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
|
|
US20170100396A1
(en)
|
2015-10-07 |
2017-04-13 |
F. Hoffmann-La Roche Ag |
Pyrrolopyrazine derivatives for use in the treatment, amelioration or prevention of influenza
|
|
SG11201803088PA
(en)
|
2015-10-15 |
2018-05-30 |
Agios Pharmaceuticals Inc |
Combination therapy for treating malignancies
|
|
WO2017087885A1
(en)
|
2015-11-19 |
2017-05-26 |
Dana-Farber Cancer Institute, Inc. |
Methods of identifying compounds that interfere with erg-driven misguidance of baf complexes in tmprss2-erg driven prostate cancers
|
|
AU2017205101B2
(en)
|
2016-01-08 |
2023-05-04 |
Breast Cancer Now |
Inhibitors of ataxia-telangiectasia mutated and Rad3-related protein kinase (ATR) for use in methods of treating cancer
|
|
ES2912909T3
(es)
|
2016-02-26 |
2022-05-30 |
Celgene Corp |
Enasidenib para su uso en el tratamiento de la leucemia mieloide aguda recidivante o refractaria
|
|
CN113336029B
(zh)
|
2016-02-29 |
2022-12-20 |
富士达株式会社 |
电梯系统
|
|
GB201604638D0
(en)
|
2016-03-18 |
2016-05-04 |
Mission Therapeutics Ltd |
Novel compounds
|
|
CN109641874A
(zh)
|
2016-05-10 |
2019-04-16 |
C4医药公司 |
用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
|
|
EP4491236A3
(en)
|
2016-05-10 |
2025-04-02 |
C4 Therapeutics, Inc. |
Heterocyclic degronimers for target protein degradation
|
|
EP3454862B1
(en)
|
2016-05-10 |
2024-09-11 |
C4 Therapeutics, Inc. |
Spirocyclic degronimers for target protein degradation
|
|
US10207998B2
(en)
|
2016-09-29 |
2019-02-19 |
Duke University |
Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof
|
|
WO2018064589A1
(en)
|
2016-09-29 |
2018-04-05 |
Dana-Farber Cancer Institute, Inc. |
Targeted protein degradation using a mutant e3 ubiquitin ligase
|
|
AU2018219292B2
(en)
|
2017-02-08 |
2024-09-26 |
Dana-Farber Cancer Institute, Inc. |
Tunable endogenous protein degradation with heterobifunctional compounds
|
|
KR20190140438A
(ko)
|
2017-02-28 |
2019-12-19 |
에피자임, 인코포레이티드 |
암 치료를 위한 smarca2의 저해
|
|
US11555031B2
(en)
|
2017-03-20 |
2023-01-17 |
The Broad Institute, Inc. |
Compounds and methods for regulating insulin secretion
|
|
US20200206344A1
(en)
|
2017-08-21 |
2020-07-02 |
Dana-Farber Cancer Institute, Inc. |
Methods for modulating the interaction between ews-fli1 and baf complexes
|
|
AU2018320673B2
(en)
|
2017-08-21 |
2023-03-30 |
Merck Patent Gmbh |
Benzimidazole derivatives as adenosine receptor antagonists
|
|
WO2019138017A1
(en)
|
2018-01-15 |
2019-07-18 |
Ucb Biopharma Sprl |
Fused imidazole derivatives as il-17 modulators
|
|
WO2019142192A1
(en)
|
2018-01-17 |
2019-07-25 |
Gavish-Galilee Bio Applications Ltd. |
New methionine metabolic pathway inhibitors
|
|
WO2019152437A1
(en)
|
2018-01-30 |
2019-08-08 |
Foghorn Therapeutics Inc. |
Compounds and uses thereof
|
|
JP2021512167A
(ja)
|
2018-01-30 |
2021-05-13 |
フォグホーン セラピューティクス インコーポレイテッドＦｏｇｈｏｒｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． |
障害を治療するための方法及び化合物
|
|
US11447502B2
(en)
|
2018-05-25 |
2022-09-20 |
Rutgers, The State University Of New Jersey |
Antibacterial agents: dual-targeted RNA polymerase inhibitors
|
|
US20210260171A1
(en)
|
2018-06-21 |
2021-08-26 |
Foghorn Therapeutics Inc. |
Methods of treating disorders
|
|
WO2019246430A1
(en)
|
2018-06-21 |
2019-12-26 |
Foghorn Therapeutics Inc. |
Methods of treating disorders
|
|
CN118666832A
(zh)
|
2018-08-17 |
2024-09-20 |
诺华股份有限公司 |
作为smarca2/brm atp酶抑制剂的脲化合物和组合物
|
|
WO2020041756A1
(en)
|
2018-08-23 |
2020-02-27 |
Foghorn Therapeutics Inc. |
Methods of treating cancer
|
|
WO2020081588A1
(en)
|
2018-10-17 |
2020-04-23 |
Dana-Farber Cancer Institute, Inc. |
Swi/snf family chromatin remodeling complexes and uses thereof
|
|
WO2020081556A2
(en)
|
2018-10-17 |
2020-04-23 |
Dana-Farber Cancer Institute, Inc. |
Non-canonical swi/snf complex and uses thereof
|
|
JP2022508155A
(ja)
|
2018-11-21 |
2022-01-19 |
フォグホーン セラピューティクス インコーポレイテッド |
がんを治療する方法
|
|
BR112021010453A2
(pt)
|
2018-12-19 |
2021-08-24 |
Leo Pharma A/S |
Composto, e, composição farmacêutica
|
|
WO2020160100A1
(en)
*
|
2019-01-29 |
2020-08-06 |
Foghorn Therapeutics Inc. |
Compounds and uses thereof
|
|
ES3032327T3
(en)
|
2019-01-29 |
2025-07-17 |
Foghorn Therapeutics Inc |
Compounds and uses thereof
|
|
US12384776B2
(en)
|
2019-01-29 |
2025-08-12 |
Foghorn Therapeutics Inc. |
Compounds and uses thereof
|
|
US11793802B2
(en)
|
2019-03-20 |
2023-10-24 |
Sumitomo Pharma Oncology, Inc. |
Treatment of acute myeloid leukemia (AML) with venetoclax failure
|
|
PH12022550578A1
(en)
|
2019-09-12 |
2024-02-19 |
Aurigene Discovery Tech Ltd |
Method for identifying responders to smarca2/4 degraders
|
|
US20220396604A1
(en)
|
2019-10-25 |
2022-12-15 |
Dana-Farber Cancer Institute, Inc. |
Compositions comprising modified smarcb1 and uses thereof
|
|
EA202192101A1
(ru)
|
2019-11-21 |
2021-12-09 |
Фогхорн Терапьютикс Инк. |
Соединения и их применение
|
|
US20230149414A1
(en)
|
2020-01-29 |
2023-05-18 |
Foghorn Therapeutics Inc. |
Compounds and uses thereof
|
|
CA3167275A1
(en)
|
2020-01-29 |
2021-08-05 |
Foghorn Therapeutics Inc. |
Compounds and uses thereof
|
|
CN115297861B
(zh)
|
2020-01-29 |
2024-07-12 |
福宏治疗公司 |
化合物及其用途
|
|
AU2021214767A1
(en)
|
2020-01-29 |
2022-07-28 |
Foghorn Therapeutics Inc. |
Compounds and uses thereof
|
|
EP4097096A4
(en)
|
2020-01-29 |
2024-02-28 |
Foghorn Therapeutics Inc. |
COMPOUNDS AND THEIR USES
|
|
US20230121497A1
(en)
|
2020-01-29 |
2023-04-20 |
Foghorn Therapeutics Inc. |
Compounds and uses thereof
|
|
WO2021183218A1
(en)
|
2020-03-13 |
2021-09-16 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for modulating the interaction between ss18-ssx fusion oncoprotein and nucleosomes
|
|
CN115867314A
(zh)
|
2020-05-20 |
2023-03-28 |
福宏治疗公司 |
治疗癌症的方法
|
|
US12383555B2
(en)
|
2020-05-20 |
2025-08-12 |
Foghorn Therapeutics Inc. |
Methods of treating cancers
|
|
JP2024509268A
(ja)
|
2021-03-09 |
2024-02-29 |
フォグホーン セラピューティクス インコーポレイテッド |
結晶形、それらを含有する組成物、及びそれらの使用方法
|
|
WO2022192621A1
(en)
|
2021-03-12 |
2022-09-15 |
Celgene Corporation |
Methods for using a hypomethylating agent to treat diseases and disorders based on gene mutation profiles
|
|
WO2022198043A1
(en)
|
2021-03-19 |
2022-09-22 |
Foghorn Therapeutics Inc. |
Therapeutic regimens of an inhibitor of the enzymatic activity of brg1 and brm
|
|
WO2023009834A2
(en)
|
2021-07-29 |
2023-02-02 |
Foghorn Therapeutics Inc. |
Methods of treating cancer
|
|
EP4504210A4
(en)
|
2022-04-08 |
2026-04-01 |
Foghorn Therapeutics Inc |
METHODS OF TREATMENT OF A SUBJECT WITH CLINICALLY SIGNIFICANT SIGNS AND SYMPTOMS ASSOCIATED WITH BLOOD CELL DIFFERENTIATION
|
|
WO2023196565A1
(en)
|
2022-04-08 |
2023-10-12 |
Foghorn Therapeutics, Inc. |
Methods of treating cancer
|
|
WO2023196560A1
(en)
|
2022-04-08 |
2023-10-12 |
Foghorn Therapeutics Inc. |
Methods of treating cancer
|
|
CN218451564U
(zh)
|
2022-08-09 |
2023-02-07 |
宁波立奇电器有限公司 |
一种双锅双风道式空气炸锅
|
|
WO2024086577A1
(en)
|
2022-10-17 |
2024-04-25 |
Foghorn Therapeutics Inc. |
Methods of reducing or preventing metastases
|
|
WO2024216136A1
(en)
|
2023-04-13 |
2024-10-17 |
Foghorn Therapeutics Inc. |
Combination therapy for the treatment of hematological cancers
|
|
WO2024216151A1
(en)
|
2023-04-13 |
2024-10-17 |
Foghorn Therapeutics Inc. |
Combination therapy for treating hematological cancers
|
|
WO2024249769A2
(en)
|
2023-06-02 |
2024-12-05 |
Foghorn Therapeutics Inc. |
Combination therapy for treating hematological cancers
|
|
WO2025080767A1
(en)
|
2023-10-10 |
2025-04-17 |
Foghorn Therapeutics Inc. |
Differentiation and maintenance dosing regimen for fhd 286 (brg1/brm inhibitor)
|
|
WO2025080769A1
(en)
|
2023-10-10 |
2025-04-17 |
Foghorn Therapeutics Inc. |
Methods of treating cancer
|